

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) A minibody that recognizes CD22.
2. (original) The minibody of claim 1, wherein the minibody is a diabody.
3. (original) A minibody of any one of (a) to (f):
 - (a) a minibody comprising the amino acid sequence of SEQ ID NO: 1 or 3;
 - (b) a minibody functionally equivalent to the minibody of (a), and comprising the amino acid sequence of SEQ ID NO: 1 or 3 wherein one or more amino acids are substituted, inserted, deleted, and/or added;
 - (c) a minibody comprising the amino acid sequences of a CDR of SEQ ID NOs: 5 and 7;
 - (d) a minibody functionally equivalent to the minibody of (c), and comprising the amino acid sequence of a CDR of SEQ ID NOs: 5 and 7 wherein one or more amino acids are substituted, inserted, deleted, and/or added;
 - (e) a minibody comprising the amino acid sequences of a CDR of SEQ ID NOs: 9 and 11; and
 - (f) a minibody functionally equivalent to the minibody of (c), and comprising the amino acid sequence of a CDR of SEQ ID NOs: 9 and 11 wherein one or more amino acids are substituted, inserted, deleted, and/or added.
4. (original) A method for producing a CD22-recognizing antibody with increased activity by converting a CD22-recognizing antibody to a low-molecular-weight antibody.

5. (original) The method of claim 4, wherein the conversion is conversion to a diabody.
6. (currently amended) The method of claim ~~4 or 5~~, wherein the activity is an apoptosis-inducing activity.
7. (currently amended) An apoptosis-inducing agent comprising the minibody of ~~any one of claims~~ claim 1 to 3, ~~or the minibody produced by the method of any one of claims 4 to 6~~, as an active ingredient.
8. (original) The apoptosis-inducing agent of claim 7 that induces tumor cell apoptosis.
9. (original) The apoptosis-inducing agent of claim 8, wherein the tumor cell is a lymphoma or leukemic cell.
10. (currently amended) An antitumor agent comprising the minibody of ~~any one of claims~~ claim 1 to 3, ~~or the minibody produced by the method of any one of claims 4 to 6~~, as an active ingredient.
11. (original) The antitumor agent of claim 10, wherein the tumor is a blood tumor.
12. (currently amended) The apoptosis-inducing agent of ~~any one of claims~~ claim 7 to 9, wherein the antibody is a diabody.
13. (currently amended) The antitumor agent of claim ~~10 or 11~~, wherein the antibody is a diabody.